Connect with us

News

Could ovarian tissue freezing delay menopause? Here’s what research shows

Scientists at Yale School of Medicine published research on possible outcomes when menopause is delayed via ovarian tissue freezing

Published

on

A new paradigm around the biological processes of menopause is capturing the attention of scientists in the US.

A small group of researchers in the US are analysing the possibility of delaying menopause in healthy women, allowing them to extend their child-bearing years, and perhaps even forestall some of the health risks and uncomfortable symptoms.

This, however, could be controversial. While some people may believe that such research could lead to life-changing benefits for women, others may think the menopause should not be “pathologised” by medical science.

At Yale School of Medicine, Kutluk Oktay, an ovarian biologist who is director of the Laboratory of Molecular Reproduction and Fertility Preservation, recently added a new chapter to this conversation by publishing research on various possible outcomes when menopause is delayed in healthy women via ovarian tissue freezing.

Oktay, who developed and performed the world’s first ovarian transplant procedure with cryopreserved tissue for a patient with a medical indication in 1999, sees a future in which healthy women could use this process of freezing tens of thousands of eggs within the ovarian tissue to stave off menopause for as long as several decades — or even prevent its onset altogether.

“For the first time in medical history, we have the ability to potentially delay or eliminate menopause,” he said.

A mathematical model to predict outcomes for delayed menopause

Using data from hundreds of previous ovarian cryopreservation and transplantation procedures and molecular studies of how ovarian follicles behave in ovarian tissue, Oktay and his colleagues built a new mathematical model to predict how long the surgery could potentially delay menopause under a range of circumstances in healthy women.

Since Oktay performed the first successful transplantation with cryopreserved tissue, ovarian tissue cryopreservation has been successfully used in cancer patients to preserve their fertility before their treatments, which can often permanently damage the egg reserve in the ovaries and trigger menopause.

During this outpatient procedure, a surgeon laparoscopically removes the whole ovary or layers of the outer portion, which contains hundreds of thousands of dormant, immature eggs, known as primordial follicles.

These tissues are then stored in sealed containers after being frozen with a specialised process and kept as low as negative 320 degrees Fahrenheit.

Freezing ovarian tissue with this specialised process preserves it for later use. At some point in the future, the surgeon reimplants the thawed tissue into the patient either laparoscopically or with a simple procedure, using methods developed by Oktay, that places the tissue under the patient’s skin while intravenous sedation is administered.

Within three to 10 days after that, this transplanted tissue regains connections with the surrounding blood vessels and restores ovarian function in about three months.

The recently published mathematical model focusing on healthy women undergoing ovarian tissue cryopreservation considers multiple factors, including the age at which a patient gets the procedure, which plays a significant role in how long menopause can potentially be delayed.

“The younger the person, the larger number of eggs she has, as well as the higher the quality of those eggs,” Oktay said.

The model accounts for women between the ages of 21 and 40. Beyond age 40, data show that the procedure is unlikely to delay menopause for a woman with average egg reserve, but this can change with the development of more efficient freezing and transplantation methods in the future.

Furthermore, the model offers insight into the ideal amount of ovarian tissue to collect. The more tissue a surgeon removes, the longer the procedure can potentially delay menopause. However, the removal of too much tissue can lead to early menopause.

“This model gives us the optimum amount of tissue to harvest for a person of a given age,” explained Oktay.

The model also takes into account the healing process after a surgeon returns the harvested ovarian tissue to the patient. During this healing process, some of the primordial follicles are lost.

Studies on animal models show that as many as 60 per cent of primordial follicles do not survive post-transplantation, leaving 40 per cent that are viable. With newer technologies, Oktay said that he believes surgeons can attain a survival rate of up to 80 per cent.

As the procedure continues to improve, he hopes to eventually achieve a 100 per cent survival rate. Thus, the model accounts for survival rates ranging from 40 per cent to 100 per cent.

Additionally, through transplanting portions of the harvested tissues over several procedures, the research indicates that menopause can be delayed even longer. For example, the team’s model shows that returning a third of the outer portion of the ovary over each of three procedures delayed menopause longer than returning all of the tissue through one surgery.

Based on the model, Oktay predicts that for most women under 40, ovarian cryopreservation can significantly delay menopause. And for women under 30, the procedure may be able to prevent menopause altogether.

Because many women lose their ability to become pregnant sooner than they desire, ovarian cryopreservation could be an appealing option for them, said Hugh S. Taylor, professor and chair of obstetrics, gynaecology and reproductive sciences at Yale School of Medicine.

“Women are also frequently deferring pregnancy until later in life for professional or social reasons,” Taylor added. “The ability to freeze and later transplant ovarian tissue offers a way to extend their fertile lifespan.”

Does delaying menopause via cryopreservation offer health benefits?

Delaying menopause with ovarian cryopreservation may confer certain health benefits associated with a later menopausal age.

Based on new research by Oktay and his colleagues, around 11 per cent of women experience late-onset natural menopause or menopause after age 55.

Studies show that women who experience menopause later may live longer and have a lower risk for a range of conditions, including cardiovascular disease, dementia, retinal disease, depression and bone loss. However, uncertainty remains over whether later menopause actually reduces those health risks.

Oktay hypothesises that those risks also may be mitigated in healthy women who delay menopause via ovarian tissue cryopreservation.

If risk for such chronic diseases is reduced in healthy women who undergo this procedure, it could be a significant benefit. However, Taylor said that “additional research is needed to determine long-term benefits as well as risks.”

In ongoing research, Oktay and his team are studying the outcomes of healthy women who have opted to delay menopause through this procedure.

Publication of these studies is far in the future, but in the meantime, the researcher said the mathematical model offers a starting point for considering the feasibility and possible benefits of forestalling menopause in healthy women.

Events

Research project of the year: What the judges want to see

Published

on

Submitting your research project for Femtech World Awards recognition can feel daunting.

What makes one project stand out from another?

After reviewing successful submissions from previous years, we’ve identified the key elements that transform good research into award-winning work.

Innovation That Solves Real Problems

Judges aren’t just looking for novelty – they’re looking for innovation that addresses genuine gaps in women’s health.

The best submissions clearly articulate a specific problem and demonstrate how their research offers a fresh approach to solving it.

Ask yourself: Does your research tackle an underserved area? Are you approaching a known problem from a new angle?

The most compelling projects often focus on issues that have been overlooked, understudied or inadequately addressed by existing solutions.

Whether you’re investigating menopause in the workplace, developing better diagnostic tools for endometriosis, or exploring mental health interventions for new mothers, clarity about the problem you’re solving is essential.

Rigorous Methodology

Strong research stands on solid foundations. Judges carefully evaluate your methodology to ensure your findings are credible and reproducible.

This doesn’t mean your research needs to be complete – early-stage projects are welcome – but you should demonstrate thoughtful research design.

Include details about your sample size, data collection methods, controls, and analytical approaches.

If you’re conducting qualitative research, explain how you’re ensuring validity. If you’re building a technological solution, describe your testing protocols.

Transparency about limitations shows intellectual honesty and strengthens rather than weakens your submission.

Measurable Impact Potential

The research projects that win hearts and awards are those with clear pathways to real-world impact.

Judges want to see beyond the research itself to understand how your work will improve women’s lives.

Consider questions like: Who will benefit from this research? How many people could be affected? What would successful implementation look like?

Whether your impact is clinical, social, economic, or policy-related, be specific.

Instead of saying “this will help women,” try “this diagnostic tool could reduce endometriosis diagnosis time from 7-10 years to under 2 years for an estimated 200 million women worldwide.”

Inclusivity and Diversity Considerations

Award-winning FemTech research recognises that women are not a monolith.

Judges increasingly value projects that consider diversity across age, race, ethnicity, socioeconomic status, disability, and geographic location.

Have you thought about how your research applies across different populations? Are you inadvertently excluding certain groups?

The strongest submissions acknowledge these considerations and, where possible, design research to be inclusive or clearly define the specific population being served.

Clear Communication

Even groundbreaking research won’t win if judges can’t understand it. The ability to communicate complex ideas clearly is crucial.

Avoid unnecessary jargon, define technical terms, and structure your submission logically.

Think of your submission as telling a story: Here’s the problem, here’s why it matters, here’s what we did, here’s what we found, and here’s why it matters for the future.

Feasibility and Sustainability

Judges appreciate ambitious research, but they also value realistic plans.

Show that you’ve thought about practical considerations: Do you have the resources to complete this work? Is your timeline reasonable?

For projects seeking commercialisation, is there a viable path to market?

Demonstrating that you’ve considered challenges and have strategies to overcome them shows maturity and increases confidence in your project’s success.

Your Passion Matters

Finally, don’t underestimate the power of genuine passion.

The researchers who win aren’t just technically proficient – they deeply care about their work and its potential to create change.

Let that commitment shine through in your submission.

Ready to submit? Find out more about the awards and enter for free here.

Continue Reading

Insight

Topical HRT protects bone density in women with period loss – study

Published

on

Transdermal HRT best protects bone density in women with functional hypothalamic amenorrhoea, a condition that stops periods, a review of trials has found.

The meta-analysis pooled randomised clinical trials involving 692 participants and found transdermal hormone replacement therapy and teriparatide increased bone mineral density by between 2 and 13 per cent.

Functional hypothalamic amenorrhoea can follow anorexia or intense exercise. Bone mineral density measures bone strength and the amount of mineral in bone.

Around half of women with the condition have low bone mineral density, compared with about 1 per cent of healthy women, and their fracture risk is up to seven times higher.

The research was conducted by scientists at Imperial College London and Imperial College Healthcare NHS Trust.

Professor Alexander Comninos, senior author of the study and consultant endocrinologist at the trust, said: “Bone density is lost very rapidly in FHA and so addressing bone health early is very important to reduce the lifelong risk of fractures.

“Our study provides much needed comparisons of all the available treatments from all available studies.

“Clearly the best treatment is to restore normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions – but that is not always possible.

“The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional treatments that are more effective.”

When FHA is diagnosed, clinicians first try to restore periods through lifestyle measures, including psychological and dietary support, but these can fail. Guidelines then recommend giving oestrogen, though the best form was unclear.

The team reviewed all prior randomised trials comparing therapies, including oral and transdermal oestrogen, and also assessed teriparatide, a prescription bone-building drug used for severe osteoporosis.

They found no significant benefit for oral contraceptive pills or oral hormone therapy.

A recent UK audit reported that about a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill for bone loss; the study suggests using transdermal therapy instead.

Comninos said: “Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.

“We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines.

“Right now, millions of women with FHA may not be receiving the best treatments for their bone health.”

Continue Reading

Insight

AI cuts interval breast cancers in Swedish trial

Published

on

An AI tool cut interval breast cancers by 12 per cent in a Swedish screening trial of more than 105,000 women.

The study also found 27 per cent fewer aggressive breast cancers detected at screening when AI was used.

Interval cancers are cancers found between routine screening appointments because they were missed at the original scan. They are often more dangerous and linked to higher death rates than cancers found at screening.

The MASAI trial is described as the first large randomised study to test whether AI can improve mammography screening, which uses low-dose X-rays to examine breast tissue for signs of cancer.

The AI tool, called Transpara Detection and developed by ScreenPoint Medical, supported radiologists in analysing mammography images.

Earlier results from the same trial showed that Transpara Detection increased cancers found by 29 per cent and reduced radiologist workload by 44 per cent compared with standard double-reading, where two radiologists independently review each scan.

The latest findings indicate higher accuracy with AI support. Sensitivity, the ability to detect cancer, was 6.7 percentage points higher in the AI group while specificity, the ability to rule out healthy cases, was maintained. Results were similar across age groups and breast density levels.

Women screened with AI had 16 per cent fewer invasive interval cancers and 21 per cent fewer large interval cancers than those in the standard screening group.

The system also helps doctors assess risk more precisely by subdividing suspicious findings into BI-RADS 4 categories A, B and C. BI-RADS (Breast Imaging Reporting and Data System) is a standardised scale that guides whether a patient needs closer monitoring, further tests or treatment.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.